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Major  histocompatibility  (H-2)  antigens  are  cell  surface  glycoproteins  that 
serve as targets for both allospecific and virus-restricted cytolytic T  lymphocytes 
(CTLs) ~ (for reviews see  references  1,  2).  However, the precise nature  of the 
molecular interactions involved in the recognition of the H-2 molecules is poorly 
understood. The nature of these interactions was originally defined by analyzing 
the  ability of T  cells  to  recognize target  cells bearing  genetically altered  H-2 
molecules. Early studies demonstrated that the determinants on the H-2 mole- 
cules that are recognized by T  cells are affected by variations that have arisen 
spontaneously in mice (3) and humans (4). All of the variants contained alterations 
in the 44,000-dalton subunit of the H-2 antigen. Subsequent studies have begun 
to map the functional regions of this peptide more accurately. 
The  H-2  antigen  is  comprised  of two  subunits--132-microglobulin  (12,000 
daltons) and  H-2 (44,000 daltons).  The portion of the H-2 subunit that sits on 
the cell surface appears to fold into three external domains (N, C 1, and C2) (5). 
Each of these domains is encoded by a  separate coding block in the H-2 gene. 
Through the application of recombinant  DNA  technology, we and  others (6- 
15)  have  begun  to  define  the  domains  of the  H-2  molecule  that  encode  the 
determinants recognized by the T  cells.  That is,  H-2 genes have been cloned, 
altered in vitro and  reintroduced into  mouse  L  cells.  The ability of T  cells to 
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recognize the  L  cells bearing altered  H-2  antigens  on  their surfaces  has  been 
examined.  The  initial  constructs exchanged the  N  and  C1  exons between  the 
H-2L  d and H-2D  d genes and suggested that allospecific and virus-restricted CTLs 
utilize determinants encoded within the N  and/or C1  domains (14,  15). 
To further define the epitopes  that  are  involved in  immune  recognition of 
these antigens,  we have constructed a  new H-2 gene. This H-2 gene was made 
by replacing the N-terminal domain (N) of the H-2L  ~ gene with the N  domain 
of the  H-2D  d gene.  The biological function of the cells expressing this hybrid 
H-2 gene on its cell surface were explored for serologic and CTL recognition. 
Materials and Methods 
Plasmid Construction.  A hybrid H-2 gene was made from restriction enzyme fragments 
using standard DNA technology (16).  In both plasmids pDd-1 and pLd-4 Sinai sites were 
located in the intervening sequences between the leader, the N, and C1 exons. In plasmid 
pLd-4, however, one additional SmaI site is present, located 5' of the leader sequence in 
the promoter region.  In order to remove this 5'  Sinai site, plasmid pLM was used in 
which the normal H-2 promoter was replaced by the metallothionein promoter (J. w., 
and J. G. S.,  unpublished results). This was done by cloning a  BamH1  partial digested 
fragment encoding the H-2L  d gene into the BglII site of plasmid pMK (I 7; J. W. and J. 
G. S., unpublished results). However, plasmid pLM contains several Sinai sites in the 3' 
end of the plasmid (17; J. W. and J. G. S., unpublished results). To remove these Sinai 
sites, a 2.2-Kb BamH1 fragment of pLd-4, encoding the 3' end of the H-2L  d gene (6) was 
ligated to the 8-Kb BamHI fragment of pLM and used to transform Escherichia coli strain 
322 (18). The resulting plasmid pLL was extensively mapped by restriction endonuclease 
cleavage to confirm the reconstruction. 
Plasmids  pLL  and  pDd-1 were  subsequently  digested  with  Smal.  A  250-bp  SmaI 
fragment of pDd-I  encoding the first external domain, was isolated and ligated to the 10- 
Kb Sinai fragment of pLL. The ligation mixture was reintroduced into E. coli LE392 by 
CaCl~-induced transfection. Colonies were screened for the insert by colony hybridization, 
using the  250-bp SmaI  fragment as a  probe.  Isolated plasmids  were checked for the 
orientation of the SmaI insert by M 13 sequencing. Briefly, plasmids were digested with 
Sau3AI and subcioned into M13 mp9. Plaques were screened for inserts using the 250- 
bp SmaI fragment as a probe. The inserts of these M 13 recombinants were sequenced by 
the dideoxy termination method (19, 20). 
Transfection  of Plasmid pDL  into  L  Cells  and Determination  of Binding of Monoclonal 
Antibodies.  Plasmid  pLD,  encoding  the  recombinant  H-2  gene,  was  introduced  into 
thymidine kinase-deficient mouse L cells (DAP-3) by DNA-mediated gene transfer using 
the herpes simplex thymidine kinase gene as a  selectable marker (21,  22).  Serological 
characterization of H-2 transformants by monoclonal antibodies having specificities for 
H-2L  d or  H-2D  d was  carried  out  by  radioimmunoassay as  described previously (13). 
Briefly, cells dissociated by trypsin treatment were seeded in 96-well  microtiter plates at 
1 ×  105 cells/ml in  150 #l culture medium and incubated overnight at 37°C in 7% or 
10% CO2 in  humidified air. After medium was removed by flicking the plate, 40 #1 of 
monoclonal antibodies  contained  in  culture  supernatant  were  added,  and  cells  were 
incubated for 45 min at 8 ° C. Cells were washed three times with culture medium and 40 
#1 of '~I-sheep anti-mouse IgG (heavy chain and light chain specific) (Amersham, Arling- 
ton Heights, IL) and diluted in medium at 1:100. Cells were incubated an additional 45 
rain  at  8°C,  followed by  three  rinses.  Cell-bound  *z~1-antibodies were  recovered by 
dissolving the cells in 100 #1 a 1% solution of Triton X-100 and radioactivity was measured 
in a 7-spectrophotometer. The cloned cell lines T1.1.1 and T4.8.3, encoding an H-2L  d 
and H-2D  d gene, and monoclonal antibodies specific for H-2D  d and a H-2L  d determinant 
have been described elsewhere (6, 9, 23, 24). 
Immunoprecipitation  of H-2 Antigens.  The cloned cell lines TI.I.I  and T9.10.3 were 
iodinated with '25I as previously described (25). The immunoprecipitation was performed MURRE  ET  AL.  169 
as described (26).  SDS-polyacrylamide gel electrophoresis was carried out on a discontin- 
uous vertical slab gel using a modification of the Laemmli procedure (27).  A gradient gel 
was made in  10-15% acrylamide. The gels were dried and exposed for 3 d. 
Assays of Cell-mediated Cytotoxicity.  BALB/c mice were immunized parenterally with 
either vesicular stomatitis virus (VSV;  107 pfu) or influenza A/PR/8/34 virus (PR8;  100 
HAU).  1 wk later the mice were sacrificed by cervical dislocation and their spleens used 
as a source of virus-immune lymphocytes. 5-d secondary in vitro antiviral CTL cultures 
were  established  with  5  x  106  primed  lymphocytes and  1  x  108  irradiated  BALB/c 
splenocytes, which were infected with either 10 pfu tsG41 VSV at permissive temperature 
or  10 EID~0 PR8 virus/cell in  17-ram Costar clusters with RPMI  1640 medium supple- 
mented with  10% fetal bovine serum (FBS), penicillin, streptomycin, L-glutamine, and 5 
x  10 -5 M 2-mercaptoethanol. Primary allospecific CTLs were generated in 5-d cultures 
of 5 x  106 naive lymphocytes derived from either C57B1/6J or C-H-2  dm~ mice cultured 
with  1 x  106 irradiated  C-H-2  din2 or C3H  or BALB/c stimulator cells using the  same 
medium. Virus-specific or allospecific effectors were harvested and dispensed in duplicate 
at 1 x  106, 3 x  105, and  1 ×  105 cells/V-bottom microtiter well (Linbro) in 0. I  ml MEM 
supplemented with  10%  FBS,  nonessential amino acids, penicillin, streptomycin, and L- 
glutamine. L cell targets, prepared by versene treatment, were divided in three portions 
and infected with either 10 pfu wt VSV or 10 EIDs0 PR8 virus, or left uninfected. L cells 
were pulsed with 0.1  mCi Na2 ~CrO4 for 1 h at 37°C, incubated an additional  1 h, and 
then washed three times. L cell targets were dispensed at 1 x  104 in 0.05 ml volumes into 
wells containing effectors, normal spleen cells or 0.1  ml 5% Triton X-100  (to measure 
spontaneous release and total release, respectively). Plates were centrifuged at 100 g and 
then incubated at 37 °C for 5 h. Supernatants (0.1  ml/well) were harvested and counted 
for 5~Cr release. Percent specific release was calculated by the formula =  100 x  (experi- 
mental cpm -  control cpm)/(total cpm -  control cpm). 
Cold Target Inhibition of CTL Activity.  Unlabeled targets were prepared by removing 
transformed L cells from flasks with versene. For each target equal portions were either 
untreated or infected with influenza A/PR/8/34  virus (10 EIDs0/cell) and incubated at 
37°C for 1 h. The cells were washed and counted and dispensed in 50-#i volumes (four 
serial twofold dilutions 2 x  106/ml to 0.25 x  108/ml in duplicate) into V-bottom microtiter 
wells.  Next,  5~Cr-labeled  targets,  prepared  as  described  above,  were  added  in  50-#1 
volumes from a  2 x  104/ml suspension.  Lastly, BALB/c effectors specific for PR8 virus 
were added in a 50-#1 volume from a 2 x  105/ml suspension. Plates were spun as described 
above and incubated for 5 h before taking aliquots of supernatant for counting. 
Results 
Construction  of a  Novel H-2Da/H-2L a Recombinant  Gene.  The  availability  of 
transformed cell lines expressing new H-2 recombinant antigens has allowed us 
to  map  serological  and  CTL  determinants  to  discrete  portions  of  the  H-2 
molecule  (13-15).  in  order  to  define  more  precisely  the  location  of  these 
determinants,  we constructed  a  hybrid  H-2  gene by replacing the  H-2L  d exon 
encoding the  N  domain with the H-2D  d exon. Several restrictions endonuclease 
cleavage sites,  including  SmaI sites,  are  conserved between  the  H-2L  d and  H- 
2D  d  sequences.  Specifically,  in  plasmids  pDd-1  and  pLL,  two  Sinai  sites  are 
present. One Sinai site is located in the intervening sequence between the leader 
and  N-exon.  Another  Sinai  site  is  between  the  N  and  C1  exon  of the  H-2D  d 
gene (Fig.  1; C.  M. and J. G. S., unpublished  results).  These constructions were 
digested  with  SmaI and  a  Sinai  fragment of the  H-2D  d gene  encoding  the  N 
domain  was  ligated  to  the  10-Kb Sinai  fragment of pLM  (Fig.  1,  panel A).  If 
correctly expressed, the product of the recombinant plasmid (pDL) would contain 
the N  domain of one transplantation  antigen and the C1, C2, TM, and internal 
domains of the other (Fig.  1, panel B). 170  DISSECTION  OF  SEROLOGICAL  AND  CYTOLYTIC  T  EPITOPES 
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FIGURE  l.  (A) Construction of a recombinant H-2 gene. Cross-hatched areas represent the 
regions coding for the metallothionein promoter. Solid and dotted areas represent the regions 
coding for H-2L  d and H-2D  a. L, N, CI, C2, M, Ib Is and I~ refer to the regions of the protein 
labeled by analogy of the H-2K  prototype structure (5).  S, Sinai. (B)  encoded by each exon  b 
Hybrid H-2L  a protein which contains the N-domain of the H-2D  d antigen. 32M refers to 32- 
microglobulin. 
Expression of the Novel Recombinant H-2 Gene in L Cells and Determination of the 
Location of  Serological Spec~cities.  To determine whether the novel recombinant 
gene is expressed when introduced into mouse L cells, DNA from this recombi- 
nant gene together with the herpes viral thymidine kinase gene, was used to co- 
transform thymidine kinase-negative mouse L cells as previously described (21, 
22).  Transformants  were  selected  in  hypoxanthine-aminopterin-thymidine 
(HAT) medium and screened with monoclonal antibodies specific for H-2L  d and 
H-2D  d specificities.  Antibody-positive  cells  were  further  characterized  with  a 
series of antibodies whose specificities were previously mapped to either  N/C 1 
or  C2  domains  of the  two  antigens.  The  results  are  shown  in  Table  I.  As 
expected,  monoclonal  antibody  28.14.8,  previously shown  to  bind  to  the  C2 
domain of the H-2L  d molecule (13), recognizes the recombined gene product of 
the transformant  T9.10.3.  Monoclonal antibody  34.2.12,  recognizing  a  deter- 
minant  of the  C2  domain  of the  H-2D  d  monoclonal  antibody  did  not  bind 
significantly  to  the  recombinant  molecule,  confirming  that  the  3'  end  of this 
gene is derived from the H-2L  a. MURRE  ET  AL. 
TABLE  1 
Monoelonal Antibody Binding to the N-C I Hybrid H-2 Antigen * 
171 
Monoclonal  Specific-  Antibody 
antibody  ity  j  class  DAP-3 
Transformed cells (12~I bound, cpm/well) 
TI.I.1-  T483-  T9.10.3- 
(LdLdLa)*  (DdDaD  a)  (DdLaL  a) 
16.1.2  KkD  k  IgG2a  2,341  --+ 23  1,128 -  19  1,952 __. 11  2,290 + 21 
17.3.3  Ia  k  IgG2a  <200  <200  <200  <200 
27.11.13  Dd&L  a  IgG2a  <200  1,331 +  18  1,650+ 11  1,703±28 
34.4.20  D  a & L  a  IgG~a  <200  1,985 + 23  1,580 _+ 28  2,253 + 20 
28.11.5  Dd&L  a  IgM  <200  438_+  15  380_+23  518_+9 
28.14.8  L  a, C2  IgG~a  <200  1,609 + 29  <200  2,018 -+ 43 
23.10.1  L  a N/C1  IgM  <200  615 -+ 18  <200  654 "4- 8 
30.5.7  L a N/C1  IgG~a  <200  1,885 -+ 33  <200  2,200 ±  18 
34.2.12  D  d C2  IgG~  <200  <200  1,428 _  21  <200 
23.5.1  D  a N/C1  IgM  <200  <200  453 _+ 5  638 -+ 31 
28.8.6  D  a N/C1  IgG2~  <200  <200  508 -+ 18  373 -+ 9 
34.4.21  D  a N/C1  IgM  <200  <200  620 -4- 5  598 -+ 9 
34.5.8  D  a N/CI  IgG2a  <200  <200  1,241 -+ 17  383 + 30 
34.1.2  D  a N/C1  IgG~a  <200  <200  1,532 -+ 38  1,980 ±  12 
* The transformed cells were placed in wells of 96-well microtiter plates at the concentration of 1 × 
10 ~ cells/well and incubated overnight. Monoclonal antibodies in supernates were added to the 
cells, and antibody binding was monitored by subsequent incubation with 12SI-sheep anti-mouse 
IgG. Each value represents mean of triplicates _+ standard deviation. 
* The origin of the gene for each domain shown in the order of the N, C 1, and C2. 
g Specificity of the antibodies for gene products and domains have been assigned previously (13, 23, 
24). 
Monoclonal  antibodies  34.4.20,  27.11.13,  and  28.11.5,  which  show  cross- 
reacting specificities, reacted in all cases with transformant  T9.10.3,  confirming 
that  the  exon  shuffling has  not  greatly altered the  conformational  structure  of 
the  protein.  Because  of the  nature  of J2~I-anti-mouse  reagents,  IgM  antibodies 
gave consistently lower counts than  IgG antibodies. 
Two  monoclonal  antibodies,  23.10.1  and  30.5.7,  specific  for  N  and/or  C1 
domain  of  H-2L d  reacted  with  the  transformed  cell  line  T9.10.3.  Thus,  the 
specificities of both  monocionals are  likely to  be  mapped  to the  C1  domain  of 
the H-2L  d antigen.  Four of the five monoclonal antibodies, with specificities for 
H-2D d determinants,  recognized  H-2  molecules on  transformed  T9.10.3,  sug- 
gesting that reactivities of these antibodies were mapped  to the N  domain of the 
H-2D d antigen. The  level of these determinants expressed on the hybrid molecule 
was comparable  to those expressed  on  native  H-2L d or  H-2D d molecules,  since 
no  major  difference  in  antibody  binding  was  found  between  the  hybrid  and 
native  molecules  of  antibodies.  However,  very  weak  binding  of  monocional 
antibody  34.5.8  (H-2D d) to  the  transformed  T9.10.3  was  detected,  which  may 
indicate that this antibody reacts with  the C1  domain  of H-2D d antigens, or to a 
conformational  determinant  dependent  upon  the  integrity  of  the  N  and  C1 
domains  of  H-2D a.  Although  most  of  the  anti-H-2D  a  and  all  of  the  anti-L  d 
antibodies presented in this paper reacted with the transformant, lack of reactivity 
was found with some additional monoclonals reactive with N  and/or  C 1 domains 
of H-2D a  or  H-2L d antigens.  These  monoclonal  antibodies have been  obtained 
recently, and their detailed characterization  will be presented  elsewhere.  Thus, 172  DISSECTION  OF  SEROLOGICAL  AND  CYTOLYT1C  T  EPITOPES 
FIGURE 2.  SDS-PAGE  analysis  of  l~I-labeled  surface  antigens  immunoprecipitated  from 
clone T1.1.1,  expressing the complete H-2L  d gene and clone T9.10.3 expressing the recom- 
binant gene. 
this antigen represents "gain and loss" alteration with respect to the serological 
specificities of the H-2D  d and H-2L  d antigen. 
Immunoprecipitation.  In  order  to  determine  the  molecular  weight  of  the 
recombinant gene product and its association with/32-microglobulin, the hybrid 
antigen was isolated from the cell surface. Membrane proteins were labeled by 
lactoperoxidase-mediated iodination of the transformed cells. The proteins were 
immunoprecipitated by monoclonal antibody 28.14.8, which recognizes a deter- 
minant of the C2 domain of the H-2L  d protein (13).  The immunoprecipitates 
were analyzed by SDS-polyacrylamide gel electrophoresis (Fig. 2). The gel shows 
clearly that the recombinant H-2 antigen has a molecular weight (45,000 daltons) 
similar to that of the wild-type H-2 molecule. Moreover, the protein is associated 
with/32-microglobulin. 
Localization  of  Determinants  Recognized  by  CTLs  Using the  Transformant 
T9.10.3.  The ability of the recombinant gene product to serve as a target for 
allogeneic and virus-specific CTLs was tested. Target cells expressing this hybrid 
H-2 molecule also enabled one to localize CTL determinants to either the N or 
C 1 domains. 
a.  Allospec~c  CTL  recognition.  CTLs  generated  by  stimulating  B6  (H-2  b) 
spleen  cells  with  C3H  (H-2 k) cells  lysed all  L  cells  (Table  II).  C-H-2  dm2  mice 
express H-2K  d and H-2D  d and background antigens of BALB/c mice, but do not 
express  H-2L  d  antigens,  therefore,  CTLs  from  cultures  of dm2  splenocytes MURRE  ET  AL.  173 
TABLE  II 
Allospecific and Virus-specific Recognition of N-C1 Recombinant Line T9.10.3 
Target cells* 
P815  TI.I.1  T4.8.3  T9.10.3  DAP 
Effector* 
LdLdLd/"  LdLaLd  DdDdD a  DaLaL d  __  H-2 gene  0  DdDaD  a 
I  BALB/c anti-VSV  50,35,21  30,26,  13  8,4,0  0,0,0  0,0,0 
BALB/c anti-PR8  77,82,29  42,37,17  40,34,23  26,21,13  0,0,0 
B6 anti-C3H  ND  !  74, 63, 48  69, 56, 30  53, 41,  37  52, 43, 22 
din2 anti-BALB/c  95, 84, 93  80, 57, 37  23, 9, 6  40, 19, 6  12,  10, 10 
lI  C3H anti-dm2  89, 88, 27  4, 0, 0  75, 47, 27  68, 51, 34  10, 3, 2 
B6 anti-C3H  22, 5, 0  56, 33,  17  72, 39, 20  74, 41,  30  71, 74, 31 
III  din2 anti-BALB/c  84,81,60  59,30,16  11,6,5  35,28,12  10,9,9 
B6 anti-C3H  ND  64, 50, 25  66, 64, 48  76, 59, 52  59, 53, 57 
*  Virus-specific effectors  were generated  by in vivo priming with either  107 pfu VSV or  100 HAU 
influenza A/PR/8/34  virus  1 wk before  sacrifice and in vitro  restimulation  of splenocytes  with 
virus-infected syngeneic cells as described in Materials and Methods. Allospecific effectors resulted 
from primary in vitro culture of splenocytes with irradiated stimulator cells. 
* Specific release  of S~Cr from  labeled target  cells,  Only appropriate  lysis is shown (that is, VSV- 
specific  lysis on  VSV-infected  targets).  Uninfected  targets  released  10%  of their  counts  in  the 
presence  of virus-specific effectors  and inappropriate  virus infected targets  were  not  lysed (data 
not shown). Effector to target ratios shown were 100, 33, and 11 to 1 for all effectors. Spontaneous 
release ranged from 10% to 23% of total counts in 5-h release assays. 
L  d and D a refer to the region of the H-2 antigen encoded by the N, C1, and C2 exon. 
I Not determined. 
stimulated  with  BALB/c  cells  are  limited  to recognizing  the  H-2L a molecule. 
These effectors  lysed all cells expressing H-2L a products (Table  II). The trans- 
formant  T9.10.3  was  recognized  less  efficiently  than  TI.I.1  (H-2L a  trans- 
formant) or cells expressing the hybrid gene possessing the N  and C 1 domains 
of  H-2L  d  (data  not  shown),  suggesting  that  some  but  not  all  determinants 
recognized  by alloreactive  CTLs are located on the C1  domain of H-2L  d. The 
loss of determinant(s) recognized by effectors specific for H-2L a can be due to a 
determinant(s) that maps in the N  domain or to an epitope(s) that is formed by 
the interaction  of both the N  and C1  domains of H-2L d. Allospecific  CTLs for 
the H-2D a antigen were prepared by sensitization of C3H splenocytes with dm2 
cells.  These  CTLs  lysed  all  lines  expressing  the  H-2D d antigen  including  the 
recombinant, T9.10.3.  This maps some allospecific  epitopes to both the N  and 
C1 domains. 
b.  Influenza  virus-specific  CTLs.  We  have  previously  shown  that  BALB/c 
effectors specific for influenza virus are restricted to both the H-2D  a and H-2L a 
molecules expressed on L cells following DNA-mediated  gene transfer (15).  In 
order to test whether influenza virus specific CTLs could recognize infected cells 
expressing the recombinant H-2 molecule, BALB/c  mice were immunized with 
PR8  virus.  Secondary  in  vitro  cultures  elicited  CTLs  that  iysed  all  of  the 
transformants shown in Table II. The recombinant T9.10.3 was recognized less 
efficiently  than T1.1.1  or T4.8.3,  suggesting that some virus-restricting  deter- 
minants were lost after recombination. 
Cold target inhibition assays were used to further map determinants detected 
by influenza virus-specific  CTLs. Specifically,  the inhibition of influenza virus- 174  DISSECTION  OF  SEROLOGICAL  AND  CYTOLYTIC  T  EPITOPES 
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FIGURE 3.  Localization  of  influenza virus  specific  epitopes by cold target inhibition:  Influenza 
A/PR/8/34 virus specific CTLs of BALB/c mice were assayed  on PR8 infected, 51Cr labeled 
(hot) targets 4.8.3 (D  a) and T1.1.1 (La). The effect on lysis  of the indicated unlabeled (cold) 
targets was then assessed. (Q) T4.8.3 infected with PR8; (O) T4.8.3  uninfected; (B) TI.I.1 
infected with PRS; (O)  TI.I.1  uninfected; (A)  T9.10.3  infected with PR8; (A)  T9.10.3 
uninfected. 
specific CTL lysis of 51Cr  labeled (hot) targets was examined in the presence of 
excess unlabeled (cold) target cells. As shown in Fig.  3,  lysis of labeled T4.8.3 
and  T I.I.1  was  partially  blocked  by  infected,  but  not  uninfected,  unlabeled 
T9.10.3  cells. Virally infected cold target cells expressing the hybrid molecule 
were  not  as  efficient  as  were  infected  cold  target  cells  expressing  the  same 
transferred gene as the hot target cells. These results suggest that some deter- 
minants that  restrict  influenza virus-specific  CTLs are  present  in  both  the  N 
domain of H-2D  a and the C1  domains of H-2L  d. 
c.  VSV-specific  CTLs.  CTLs from BALB/c mice recognize VSV in association 
with H-2L  a, but not with H-2D  a (28).  Recently, we have shown that restricting 
elements recognized by VSV-specific effector cells are located in the N  and/or 
C1  domain of the  H-2L  a antigen (15).  Transformant T9.10.3  was used in an 
attempt  to  further  map  these  VSV-restricting  elements.  BALB/c  mice  were 
immunized with  VSV  virus and these  VSV-specific  CTLs lysed infected P815 
and TI.I.1  targets efficiently. However, infected T4.8.3 and T9.10.3  were not 
lysed by VSV-specific effector cells. Thus, it appears that determinants for VSV- 
specific CTLs either map exclusively to the N  domain or are dependent upon 
conformation that is lost when external domains are exchanged. 
Discussion 
Major histocompatibility antigens are the primary target of both humoral and 
cellular responses. The portions of these antigens that are involved in the specific 
interactions that permit the specific recognition of cells bearing these antigens 
remains  uncertain.  One  approach  to  dissecting  the  H-2  antigen  has  been  to 
examine the ability of antisera and T  cells to recognize genetically altered H-2 
antigens on the cell surface. These studies have been extended by the application 
of recombinant  DNA  technology  to  generate  hybrid  H-2  genes  that  encode 
novel  H-2  molecules.  We  have  described  here  one  such  hybrid  H-2  antigen- 
formed by exchanging the N  domains of the H-2D  d and H-2L  d antigens. Using MURRE  ET  AL. 
TABLE III 
Tentative Assignment of Polymorphic Determinants  in the External 
Domains of the H-2 Antigen 
Antigen 
Domain 
N  C1  C2 
H-2L  d  30.5.7  28.14.8 
23.10.1 
H-2D  e  23.5.1  34.5.8?  34.2.12 
28.8.6 
34.1.2 
34.4.21 
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cells expressing this hybrid H-2 antigen, we have further mapped serological and 
CTL determinants on the H-2 molecule. 
Previously we had located serological and CTL determinants to the N and/or 
C1 domains of H-2D  a and H-2L  a using hybrid H-2 antigens created by exchang- 
ing exons from the genes of these two antigens.  The recombinant H-2 antigens 
expressed on L cells following DNA-mediated gene transfer were used as targets 
for CTLs that  were either  H-2D  a or H-2L  a restricted.  CTLs specific for four 
different  antigens  were  used.  All  four  different  types  of CTLs  would  only 
recognize L cells expressing the N  and C1  domains of the restricting allele (14, 
15). By contrast, serological determinants were identified that mapped to the C2 
domain as well as the N and C1 domains of these H-2 antigens (13). 
The hybrid H-2 antigen  described here has been used to further map deter- 
minants  that  were previously mapped  to the  N-terminal  two domains  (N  and 
C1).  Serological determinants  map to both the N  and C1  domains (Table III). 
Furthermore, there are aliospecific (Table II) and influenza virus-specific deter- 
minants that can be mapped to either the N  or C1  domains (Table II and  Fig. 
3). Since CTLs and antibodies could recognize this hybrid molecule, we suggest 
that the conformation of the hybrid molecule is not grossly altered from that of 
the H-2L  a or H-2D  a molecule.  However, there has clearly been a  loss of some 
determinants  recognized  by the  population  of CTLs;  these  determinants  are 
either localized to the domain that is missing in the recombinant molecule or to 
epitopes comprised  of the  interaction  of the  N  and  C1  domains  in  the  native 
molecule. We assume that different CTL clones, although specific for the same 
protein, are interacting with different portions of the H-2 antigen. This conclu- 
sion was also made from studies of the ability of CTLs to recognize mutant H-2 
molecules (29-32). 
Although  influenza  virus  and  aliospecific CTLs could  recognize  the  hybrid 
H-2 antigen,  VSV-specific CTLs could not recognize  VSV  in  association  with 
the  hybrid antigen.  This  finding  suggests that  either  the  conformation  of the 
hybrid  antigen  is  sufficiently altered  to  prevent  the  VSV-specific  CTLs  from 
recognizing the cells expressing the hybrid antigen or the VSV determinants are 
exclusively located on the N domain of the H-2L  a antigen.  It should be remem- 
bered that this analysis has been performed with uncloned CTL populations.  It 
is possible that a minor population of VSV specific clones exists that can recognize 
VSV in association with the C 1 domain. We are currently constructing the hybrid 176  DISSECTION  OF  SEROLOGICAL AND  CYTOLYTIC T  EPITOPES 
antigen in which the N domain is derived from the H-2L  d gene. L cells expressing 
this hybrid antigen should be useful in determining which of these models are 
correct. 
We have used a  new hybrid H-2  antigen to further map the portions of the 
H-2 antigen that act as restricting elements for CTLs. The important conclusion 
of this analysis is that different CTLs utilize different portions of the H-2 antigen 
and in particular that there are sites on the C 1 domain of the H-2L  d antigen that 
are recognized by influenza-specific CTLs but not VSV-specific CTLs. Eventually 
further studies of this type, in conjunction with protein chemical studies, may 
reveal the precise molecular nature of the interactions that are involved in H-2- 
restricted recognition of target cells by CTLs. 
Summary 
A novel H-2 gene in which the first external (N) domain of the H-2L  d antigen 
was replaced  with that of the  H-2D  d antigen was constructed and  introduced 
into  L  cells.  A  transformant expressing  the  products  of the  hybrid gene  was 
studied  for  binding  to  monocional  antibodies  specific  for  H-2L  d and  H-2D  d 
antigens. It was found that serological determinants are distributed both in the 
N  (D d) and C1  (L  d) domains.  Determinants recognized by allospecific cytotoxic 
T  iymphocytes (CTLs) and virus-specific CTLs also mapped  to the  N  and C1 
domains.  Determinants  recognized  by vesicular stomatitis virus  (VSV)-specific 
effect cells,  however,  were  not present  on  the  recombinant  molecule.  These 
results  show  that  a  recombinant  gene  of two  H-2  antigens in  which  the  first 
external domain has been reshuffled can express a  functional H-2 antigen that 
can then be used to map serological and CTL determinants to specific domains. 
Received  for publication  6 February 1984 and in revised form 3 April 1984. 
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